Influence of genetic polymorphisms in drug metabolism enzymes and transporters on pharmacokinetics of different fluvastatin formulations

Qian XIANG; Jun-Yu XU; Ling-Yue MA; Nan ZHAO; Xiao-Dan ZHANG; Qiu-Fen XIE; Zhuo ZHANG; Xia ZHAO; Yi-Min CUI.
Chinese Journal of Pharmacology and Toxicology ; (6): 317-317, 2018.
Artículo en Zh | WPRIM | ID: wpr-705346

Documentos relacionados

  1. Population pharmacokinetics and pharmacogenetics of apatinib in adult cancer patients.
  2. A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study.
  3. Physiologically-based pharmacokinetic modeling-guided rational combination of tacrolimus and voriconazole in patients with different CYP3A5 and CYP2C19 alleles.
  4. The influence of CYP3A5*3 and BCRPC421A genetic polymorphisms on the pharmacokinetics of felodipine in healthy Chinese volunteers.
  5. Physiologically based pharmacokinetic modeling of tacrolimus for food-drug and CYP3A drug-drug-gene interaction predictions.
  6. Effect of hepar-protecting Wuzhi capsule on pharmacokinetics and dose-effect character of tacrolimus in healthy volunteers.
  7. Single-Nucleotide Polymorphism of CYP3A5 Impacts the Exposure to Tacrolimus in Pediatric Renal Transplant Recipients: A Pharmacogenetic Substudy of the TWIST Trial.
  8. Association between pharmacokinetics of lenvatinib in healthy subjects and genetic polymorphisms of <i>ABCB1 3435C>T</i> and <i>ABCB1 2677G>T/A</i>.
  9. Genetic polymorphisms of pharmacogenomic VIP variants in the Lahu population from Yunnan Province.
  10. Results of ASERTAA, a Randomized Prospective Crossover Pharmacogenetic Study of Immediate-Release Versus Extended-Release Tacrolimus in African American Kidney Transplant Recipients.